Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | Pembrolizumab plus CRT shows long-term benefit in PD-L1-rich HNSCC: KEYNOTE-412

Barbara Burtness • 1 Jun 2026
ASCO 2026
Head and Neck Cancer Antibodies Pembrolizumab
KEYNOTE-412

Barbara Burtness, MD, Yale School of Medicine, New Haven, CT, discusses the findings from the population subgroup analysis of the Phase III KEYNOTE-412 trial (NCT03040999) in head and neck squamous cell carcinoma (HNSCC). She highlights that that pembrolizumab with chemoradiation (CRT) delivered a significant advantage in patients with PD-L1-rich tumors, with a 12% difference in five-year event-free survival (EFS) and a 10% difference in five-year overall survival (OS). This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Barbara Burtness

OrigAMI-4: dual EGFR/MET targeting demonstrates durable responses in pretreated HNSCC
3:12
OrigAMI-4: dual EGFR/MET targeting demonstrates durable responses in pretreated HNSCC
Barbara Burtness • 1 Jun 2026
Key advances in head and neck cancer from ASCO 2026
2:49
Key advances in head and neck cancer from ASCO 2026
Barbara Burtness • 1 Jun 2026
Current and upcoming clinical biomarkers for head and neck cancer
3:00
Current and upcoming clinical biomarkers for head and neck cancer
Barbara Burtness • 15 Apr 2026
Challenges & emerging therapies in HPV-independent head & neck cancer
6:33
Challenges & emerging therapies in HPV-independent head & neck cancer
Barbara Burtness • 15 Apr 2026

Related Videos

NRG-HN015: Phase II trial of perioperative systemic therapy in recurrent head and neck cancer
3:11
NRG-HN015: Phase II trial of perioperative systemic therapy in recurrent head and neck cancer
Nabil Saba • 1 Jun 2026
INO-3107 and B-cell immunity: implications for HPV-associated cancers
1:29
INO-3107 and B-cell immunity: implications for HPV-associated cancers
Nabil Saba • 1 Jun 2026
B-cell responses in recurrent respiratory papillomatosis treated with DNA immunotherapy INO-3107
3:02
B-cell responses in recurrent respiratory papillomatosis treated with DNA immunotherapy INO-3107
Nabil Saba • 1 Jun 2026
Phase III MACE trial: metronomic chemotherapy after surgery in oral cavity squamous cell carcinoma
2:40
Phase III MACE trial: metronomic chemotherapy after surgery in oral cavity squamous cell carcinoma
Nandini Menon • 31 May 2026
The content of VJOncology is intended for healthcare professionals